Genomic Vision climbs 14% on Friday's trading on the Paris Stock Exchange, having confirmed that it has the necessary financial resources to pursue its development in 2023.

As of March 31, the biotech company specialized in the analysis of genome modifications had a cash position of 43,000 euros, compared with 760,000 euros a year earlier.

However, the company also points out that it has a net balance of 23.96 million euros from a 15-tranche OCABSA financing line concluded last year with Winance.

In the first quarter, revenues were up 12% to 435,000 euros, with sales up 13% to 312,000 euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.